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Abstract
A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer’s disease (AD)
and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current
health system to find and diagnose patients with early AD pathology. This may be related in part to the limited
capacity of the current health systems to select those people likely to have AD pathology in order to confirm the
diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative
review, we summarize the literature on candidate blood tests for AD that could be implemented in primary care
settings and used for the effective identification of individuals at increased risk of AD pathology, who could be
referred for potential inclusion in clinical trials or future approved treatments following additional testing. We give
an updated account of blood-based candidate biomarkers and biomarker panels for AD-related brain changes. Our
analysis centres on biomarker candidates that have been replicated in more than one study and discusses the need
of further studies to achieve the goal of a primary care-based screening algorithm for AD.
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Introduction
Alzheimer’s disease (AD) is characterized by the accumula-
tion of extracellular amyloid β (Aβ) plaques, intraneuronal
inclusions (neurofibrillary tangles) composed of truncated
and phosphorylated forms of the microtubule-stabilizing
protein tau, dystrophic neurites, loss of synapses and neu-
rons, and a prominent gliosis that involves changes in the
morphology and function of microglia and astrocytes [1].
Currently, we have validated biomarkers for amyloid path-
ology (Aβ positron emission tomography [PET] and the ra-
tio of 42 over 40 amino acid long Aβ cerebrospinal fluid
[CSF Aβ42/Aβ40]) [2], as well as tau dysfunction and ag-
gregation (cerebrospinal fluid [CSF] total or phosphorylated
tau and tau PET) [3]. CSF and PET examinations are, how-
ever, far from standard tests in general practice and, given
the high prevalence of the disease, alternatives such as
blood-based biomarkers would represent a significant de-
velopment, even as screening tools to determine who
should be referred to a memory clinic for specific testing.
Here, we review recent developments in the field of blood
biomarkers for AD and discuss the results in the context of
the quests to improve diagnostic algorithms and facilitate
clinical trials of novel candidate drugs.
Blood biomarkers – general considerations
Measuring biomarkers for brain diseases in the blood
poses a number of challenges that demand sensitive and
specific assays and careful validation work. Brain-derived
biomarkers are typically present at relatively low concen-
trations in the blood because of the blood-brain barrier
preventing free passage of molecules between the CNS
and blood compartments. In addition, some of the bio-
markers related to AD pathology are expressed in
non-cerebral tissues, which may confound their meas-
urement in the blood. Further, in blood, there may be
heterophilic antibodies (endogenous antibodies that
react with the antibodies of the immunochemical test to
measure the biomarker), which may give falsely high or
low results. These types of antibodies are much less of a
problem in CSF where antibody levels are much lower.
Finally, the analyte of interest may undergo proteolytic
degradation by various proteases in plasma. Below, we
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discuss recent developments of biomarkers for the
pathological processes involved in AD. We discuss bio-
marker tests that are directed against a single patho-
logical change and biomarker panels that may reflect
tissue reactions to such changes.
Targeted blood-based biomarkers
Plasma Aβ
Early results on plasma Aβ, described in the AlzBiomar-
ker database (https://www.alzforum.org/alzbiomarker),
revealed no consistent change in either plasma Aβ42 or
Aβ40 in AD [4]. This result was most likely due to
assay-related difficulties; plasma Aβ measurements may
be influenced by matrix effects (mainly other plasma
proteins binding Aβ) and the analytical sensitivities of
the first assays did not allow for diluting away such
matrix effects. In 2011, an ultrasensitive Single molecule
array (Simoa) assay for Aβ42 was published [5]. A cor-
relation of plasma with CSF Aβ42 emerged and the im-
proved analytical sensitivity clarified that the ratio of
Aβ42 to Aβ40 in plasma was reduced in amyloid
PET-positive individuals in a manner similar to CSF
Aβ42/Aβ40, although with less marked separation [6, 7].
A few years ago, reliable immunoprecipitation mass
spectrometry (IP-MS)-based assays for Aβ40 and Aβ42
were described showing a decrease in the plasma Aβ42/
Aβ40 ratio (similar to the CSF test) with around 90%
diagnostic accuracy [8, 9]. These are highly promising
developments that have spurred several method com-
parison and standardization studies that are just about
to start. These new assay formats do not solve the con-
founding problem with non-cerebral expression of Aβ,
e.g., in blood platelets [10], which affects the specificity
of the test for cerebral Aβ plaques, but still represent an
important step forward.
Plasma tau
In the dementia stage of AD, plasma tau concentrations,
measured using ultrasensitive assays, are increased com-
pared with cognitively normal control individuals, but
not as clearly as in CSF [11], which is a well-replicated
finding [4]. There is little clarity on the application of
these findings to intermediary participants in the mild
cognitive impairment (MCI) stage of the disease with re-
ports being less clear [12]. Nevertheless, in a recent
paper, Mielke and colleagues examined the relationship
of plasma T-tau concentration, determined by Simoa,
with cognitive decline in 458 participants from the Mayo
Clinic Study on Aging and found high plasma T-tau as-
sociated with faster clinical disease progression [13]. An-
other study prospective cohort study used data from the
US community-based Framingham Heart Study with
replication in the Memento study, and found that
plasma T-tau was strongly associated with incident AD
dementia [14]. Mielke et al. also developed an assay for
tau phosphorylated at amino acid 181 [15]. Plasma P-tau
concentration, measured using this assay, was associated
with both Aβ and tau PET, as well as with other
AD-associated phenotypes [15]; these associations were
stronger than those obtained using the plasma T-tau
test. The general findings of this study resonate well with
two studies showing increased plasma P-tau concentra-
tion in AD, as determined using immunomagnetic re-
duction technology [16] and Simoa [17], respectively.
Plasma neurofilament light
A well-replicated biomarker for neurodegeneration in
AD is plasma neurofilament light (NfL), which is an
intra-axonal structural protein that leaks into body fluids
upon axonal injury irrespective of cause [18]. Serum or
plasma levels of NfL (either matrix has good efficacy)
correlate strongly with CSF NfL, are increased in several
non-AD neurodegenerative diseases and are increased in
both familial and sporadic AD [18]. In familial AD, the
levels increase in the time window around 10 years prior
to expected clinical disease onset [19]; in sporadic dis-
ease the changes may appear slightly later and may also
be influenced by age-related changes (NfL concentration
increase around 3% per year in CSF in normal aging
[20]), or non-AD pathologies [21]. Altogether, plasma or
serum NfL may be a reliable blood biomarker for neuro-
degeneration in AD and other neurodegenerative
diseases.
Panels of blood-based biomarkers
Protein biomarker panels
It has been suggested that panels of markers may out-
perform single candidate markers for diagnosing, prog-
nosing and characterising AD [22]. Thus, a number of
multivariate blood-based biomarker panels have been
proposed for classifying the disease and its pathology. A
large number of reports show efficacy of stratifying cases
from controls using multivariate panels of protein
markers. Ray et al. published one of the first of these
studies, which identified 18 plasma proteins whose com-
bined signature could distinguish AD patients from con-
trols with 90% accuracy, as well as identify MCI patients
who were at risk for progression to AD within five years
[23]. The same group subsequently published results
from independent samples detailing that many of the 18
proteins originally identified were also associated with
CSF levels of Aβ and tau [24]. However, other attempts
to replicate the original findings have not been success-
ful. Marksteiner and colleagues found that only five out
of 16 of the original 18 markers had significantly differ-
ent concentrations in MCI and AD patients vs. controls
[25]. They found the sensitivity and specificity of the
panel for identifying AD and MCI to be 65–75% and
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52–63%, respectively [25]. Similarly, Soares et al. found
the diagnostic accuracy of the panel to be 60% [26],
whilst Björkqvist et al. reported an area under the curve
(AUC) of 63% [27]. Soares et al., after failing to replicate
efficacy in the Ray panel, proposed an alternative
89-analyte panel with a diagnostic accuracy of 70% [26].
Subsequently, there have been numerous contributions
of multivariate signatures for differentiating AD and/or
MCI patients from controls [28–39], as well as a number
of review articles [22, 40–43]. Two studies of most note
include contributions by O’Bryant and colleagues [44]
and Doecke and colleagues [45] who identified algorith-
mic signatures of multivariate analytes in large,
well-characterised cohorts with AUC characteristics of
at least 93% in serum and plasma, respectively. Doecke
et al. also validated their signature in a second cohort
with an AUC of 85% [45]. Many of the analytes identi-
fied across these studies are related to amyloidosis and/
or inflammation, but still there has been a notable lack
of harmonisation and replication of the findings. This is
an area of research that has been much scrutinised, with
a number of considerations and recommendations being
made by O’Bryant and colleagues regarding study design,
pre-analytical protocols and assay-related issues [46–49].
Panels of blood-based biomarker-associated disease
phenotypes
Further to case-control studies, blood-based biomarker
panels have been designed to estimate disease-related phe-
notypes, such as cognitive decline, brain atrophy and neo-
cortical Aβ deposition. Inflammatory markers [50–52], as
well as proteins associated with the complement cascade
[53], have reported associations with cognitive perform-
ance, cognitive decline and clinical progression. Most of
these contributions also examined the association of prote-
omic signatures with brain volumetry finding similar signa-
tures [50, 54–56]. Reports suggest that such signatures are
able to explain approximately one third of the between sub-
ject variation observed in brain volumes [54, 57].
Blood biomarkers able to identify AD in its earliest
stages are predicted to have the most impact for use as a
screening tool. The early timing of abnormal levels of
neocortical Aβ deposition make it the ‘gold standard’ for
early identification of disease, and therefore blood signa-
tures associated with neocortical Aβ deposition have re-
ceived considerable interest. Burnham et al. identified
six plasma proteins that contributed to a signature that
was able to estimate levels of neocortical Aβ deposition
in the AIBL cohort with a sensitivity and specificity of
80 and 82%, respectively [58]. Validation of this signa-
ture in ADNI samples resulted in 79% sensitivity and
76% specificity [58]. The same group published
follow-up results 54 months later, detailing the predictive
ability of the same signature for identifying progression
towards disease; cognitively normal individuals consid-
ered at risk by the signature progressed to MCI or AD
with an odds ratio of 2.4 in comparison to those consid-
ered not at risk [59]. MCI participants considered at risk
by the signature progressed to AD with an odds ratio of
12.3 in comparison to those considered not at risk [59].
Kiddle et al. similarly reported a signature that was asso-
ciated with neocortical Aβ deposition, identifying 13
markers which were able to explain over 30 % of the be-
tween subject variation observed in neocortical Aβ de-
position [60]. Other studies with the same aim of
inferring neocortical Aβ deposition from a blood bio-
marker signature have reported efficacies of between 58
and 78% [61–63]. A replication study by Voyle and col-
leagues found pancreatic polypeptide and IgM to correl-
ate with neocortical Aβ deposition, with IgM also
correlating with neocortical Aβ deposition within cogni-
tively normal participants [63]. Again, the signatures
across these contributions aligned with both inflamma-
tory response and the complement cascade.
Metabolomics
Recent advances in nuclear magnetic resonance and
mass spectroscopy, coupled with high performance li-
quid/gas chromatography have allowed the dynamic
evaluation of thousands of metabolites, reflecting func-
tional networks of downstream changes of the genome,
transcriptome and proteome. Metabolic changes in
plasma demonstrating a separation between controls
and AD were reported by Greenberg et al. [64], with the
two most influential metabolites being glycerophospho-
choline and d-glucosaminide. Another contribution from
Oresic et al. demonstrated metabolites that were differ-
entially expressed in MCI participants who did and did
not progress to AD within a 2-year time frame, with this
finding being specifically driven by 2,4-dihydroxybuta-
noic acid [65]. Trushina and Mielke discuss results sug-
gesting beta-alanine, aspartate and aspargine, alanine,
l-cysteine, l-methionine, methionine–cysteine–glutam-
ate, l-arginine, lysine and bile acid biosynthesis and me-
tabolism were significantly different between controls
and AD [66].
With links between cardiovascular disease and AD be-
ing drawn, as well as some promising results from life-
style intervention on cognitive performance [67], lipid
evaluation has become another area of interest in the
search for blood-based biomarkers of AD. Two recent
pilot studies have shown levels of lipids to differ signifi-
cantly between mutation carriers and non-carriers in a
study on familial AD [68], as well as AD and controls in
a sporadic AD study [69]. However, neither study was
able to use these profiles to accurately discriminate be-
tween the respective classes. Mapstone and colleagues
were able to successfully discriminate AD from controls
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with 90% sensitivity and specificity in two separate stud-
ies. Firstly, using a panel of 10 lipids [70] and secondly
with a panel of 22 lipids combined with an amino acid
and a biogenic amine [71]. However, an independent
group was unable to validate the findings from the
10-lipid panel in larger studies [72].
miRNA biomarker panels
Epigenetics are also of increasing interest to the field,
with gene regulation by micro RNA (miRNA) represent-
ing one such focus for biomarker discovery. It is
hypothesised that miRNAs are transported within lipo-
somes, HDLs, exosomes and other proteins protecting
the miRNA from degradation. Leidinger et al. first re-
ported a panel of 12 miRNAs able to discriminate AD
from controls with an accuracy of 93% [73]. The panel
also had the ability to discriminate AD patients from pa-
tients with MCI, multiple sclerosis, parkinsonism, major
depression, schizophrenia, and bipolar disorder with ac-
curacies of 74–78% [73]. Other studies identifying panels
of miRNAs have been reported to discriminate between
AD patients and controls with accuracies between 75
and 95% [74–76]. A recent review of miRNAs as bio-
markers for AD is provided by Nagaraj and colleagues
[77] where they report 136 individual miRNAs to be sig-
nificantly altered between AD and control states from
the literature. Of these 136 miRNAs, 36 were independ-
ently validated and reported in two or more contribu-
tions, with hsa-miR-125b being reported the most, 6,
times.
Exosomes
This is a hot and controversial topic in the field of
blood-based biomarkers for AD. Initial reports, in which
neuronally derived exosomes were isolated from serum
using antibodies against CNS-enriched antigens, lysed
and analysed for AD-related biomarkers, showed prom-
ising results [78, 79], but the protocols are hard to follow
and it is at the moment difficult to draw any strong con-
clusions on where this field is going.
Future perspective
As instruments for quantifying blood biomarkers be-
come more sensitive and the understanding and imple-
mentation of standardisation procedures for sample
processing and analysis are increased, the field moves
ever closer to the quest for blood biomarkers in AD.
These improvements appear to have provided a shift in
the most recent literature, away from multiplexed assays
that were popular approximately 5 years ago, back full
circle to single candidate markers that were also the
focus of investigations 10–15 years ago. The candidate
markers showing the most promise as markers for AD
are plasma Aβ42/Aβ40 ratio, tau and NfL but there is
also promising data on new panels that may represent
tissue responses to AD-related pathologies. However,
replication and more detailed analyses are required to
understand their merits as potential screening, diagnos-
tic, prognostic or monitoring markers of the disease. An
important goal will be to develop a screening/triage al-
gorithm based on blood tests for Aβ pathology and neu-
rodegeneration that could be implemented in primary
care settings and used for the effective identification of
individuals who could be referred for further testing
using CSF and PET markers and potential inclusion in
clinical trials or future approved treatments. To validate
such candidate algorithms, the AD biomarker research
community needs to collaborate with primary healthcare
specialists to establish new primary care-based cohorts
that are evaluated using currently available gold standard
measures of AD pathology (CSF and/or amyloid PET in
specialised memory clinics) following application of the
index test (the blood-based biomarker algorithm). When
validated, such a diagnostic algorithm would facilitate
AD drug development and prepare effective clinical
pathways for the advent of disease-modifying therapies
targeted against amyloid pathology.
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